Simulations Plus, Univ. of Pittsburgh partner to evaluate large-molecule drugs

By The Science Advisory Board staff writers

Medical simulation software company Simulations Plus and the University of Pittsburgh Drug Discovery Institute (UPDDI) have jointly received a phase I grant from the U.S. National Institutes of Health (NIH)-funded Small Business Innovation Research (SBIR) grant to support their large-molecule safety collaboration.

As a result of the funding from the NIH, Simulation Plus' Dilisym Services (DSS) division will combine its software with UPDDI's biomimetic human liver microphysiological systems (vLAMPS) experimental liver model and the microphysiology systems database to predict the safety of large molecules such as proteins for treating diseases.

In the first phase of the project, a beta version of software will be constructed and vLAMPS testing will be performed for several large molecules captured in the database. If the objectives are successfully completed, Simulation Plus and UPDDI will then apply for a larger phase II grant to fully fund development of a joint commercial offering, they said.

Copyright © 2021

To read this and get access to all of the exclusive content on The Science Advisory Board create a free account or sign-in now.

Member Sign In:
MemberID or email address:  
Do you have a password?
No, I want a free membership.
Yes, I have a password:  
Forgot your password?
Sign in using your social networking account:
Sign in using your social networking